B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SAB Biotherapeutics, Inc.

SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers EBS SABS SABSW
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Tickers SABS SABSW
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Strengthens Senior Management Team with Appointment of Kipp Erickson, PhD as Chief Operating Officer
From SAB Biotherapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.